Approach & Progress
NodThera is unlocking the significant therapeutic potential of NLRP3 inflammasome activation inhibitors through our novel drug discovery platform.
Building on our knowledge of the medicinal chemistry, biological activity and mechanism of action of NLRP3 inflammasome inhibitors, we are creating a next-generation pipeline of small molecules that are optimized for potency, PK and tissue penetration. We are also optimizing for structural attributes that enable individual candidate molecules to be targeted to specific disease indications.
Our lead molecules are progressing through preclinical development. We have advanced our lead development candidate, NT-0167, into pre-IND testing and are leveraging patient-derived samples and advanced bioinformatics to further characterize the candidate as we rapidly progress toward the clinic.
We plan to target a range of diseases where NLRP3 overactivation has been implicated, from fibrosis (including NASH and idiopathic pulmonary fibrosis) to neurodegenerative diseases.
Inflammatory bowel disease